Bedaquiline-linezolid regimen noninferior to standard treatment for tuberculosis
1. In this randomized control trial, an eight-week bedaquiline-linezolid regimen was noninferior to standard 24-week treatment for tuberculosis. 2. The ...
1. In this randomized control trial, an eight-week bedaquiline-linezolid regimen was noninferior to standard 24-week treatment for tuberculosis. 2. The ...
1. A 24-week regimen of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) resulted in lower mortality, treatment failure, and discontinuation compared ...
1. Compared to a 9-month injectable-containing (control) regimen, both bedaquiline-containing oral regimens had more favourable outcomes, such as negative cultures. ...
1. At 24 months, treatment success rate was numerically greater in the shorter-regimen group versus conventional therapy, satisfying the noninferiority ...
1. At 24 months, treatment success rate was numerically greater in the shorter-regimen group versus conventional therapy, satisfying the noninferiority ...
1. Four bedaquiline-pretomanid-linezolid treatment groups had a favorable outcome for the treatment of drug-resistant tuberculosis. 2. The treatment group with ...
1. For children with non-severe tuberculosis, 4 months of antituberculosis treatments was non-inferior to 6 months of antituberculosis treatments. 2. ...
1. For children with non-severe tuberculosis, 4 months of antituberculosis treatments was non-inferior to 6 months of antituberculosis treatments. 2. ...
1. Rifapentine-moxifloxacin treatment was shown to be non-inferior compared to standard therapy for tuberculosis. 2. Rifapentine without moxifloxacin treatment was ...
1. Rifapentine-moxifloxacin treatment was shown to be non-inferior compared to standard therapy for tuberculosis. 2. Rifapentine without moxifloxacin treatment was ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.